References
- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. https://doi.org/10.3322/caac.2159010.3322/caac.21590
- 2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancerstatistics 2018: GLOBOCAN estimates of incidence and mortality World wide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020;70(4):313.10.3322/caac.21492
- 3. Kuban DA, Tucker SL, Dong L, et al. Long-termresults of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74. https://doi.org/10.1016/j.ijrobp.2007.06.05410.1016/j.ijrobp.2007.06.054
- 4. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464-73. https://doi.org/10.1016/S1470-2045(14)70040-310.1016/S1470-2045(14)70040-3
- 5. Cilla S, Deodato F, Digesù C, Macchia G, Picardi V, Ferro M, Sallustio G, De Spirito M, Piermattei A, Morganti AG. Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases. Med Dosim. 2014 Spring;39(1):108-16. https://doi.org/10.1016/j.meddos.2013.11.001. Epub 2013 Dec 15. PMID: 24342167.10.1016/j.meddos.2013.11.001
- 6. Saracino B, Petrongari MG, Marzi S, et al. Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control. Cancer Med. 2014;3(5):1313-1321. https://doi.org/10.1002/cam4.27810.1002/cam4.278
- 7. Pacelli R, Caroprese M, Palma G, et al. Technologicalevolution of radiationtreatment: Implications for clinical applications. Semin Oncol. 2019;46(3):193-201. https://doi.org/10.1053/j.seminoncol.2019.07.00410.1053/j.seminoncol.2019.07.004
- 8. Cuccia F, Mazzola R, Arcangeli S, et al. Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori. 2019;105(6):516-523. https://doi.org/10.1177/030089161986784610.1177/0300891619867846
- 9. Morikawa LK, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011;80(1):6-16. https://doi.org/10.1016/j.ijrobp.2010.11.07410.1016/j.ijrobp.2010.11.074
- 10. Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reachconsensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383-7. https://doi.org/10.1016/j.ijrobp.2008.08.00210.1016/j.ijrobp.2008.08.002
- 11. Liang J, Wu Q, Yan D. The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73(3):935-43. https://doi.org/10.1016/j.ijrobp.2008.10.01910.1016/j.ijrobp.2008.10.019
- 12. Ramiandrisoa F, Duvergé L, Castelli J, et al. Détermination des marges du volume cible anatomoclinique au volume cible prévisionnel pour la radiothérapie du cancer prostatique [Clinical to planning target volume margins in prostate cancer radiotherapy]. Cancer Radiother. 2016 Oct;20(6-7):629-39. French. https://doi.org/10.1016/j.canrad.2016.07.09510.1016/j.canrad.2016.07.095
- 13. Piotrowski T, Kaczmarek K, Bajon T, et al. Evaluation of image-guidance strategies for prostate cancer. Technol Cancer Res Treat. 2014;13(6):583-91. https://doi.org/10.7785/tcrtexpress.2013.60025810.7785/tcrtexpress.2013.600258
- 14. Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiationtherapy: A RadiationTherapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012;83:e353-e362. https://doi.org/10.1016/j.ijrobp.2012.01.02310.1016/j.ijrobp.2012.01.023
- 15. International Commission on Radiation Units and Measurements Report 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 2010;10(1). https://doi.org/10.1093/jicru/ndq00210.1093/jicru/ndq002
- 16. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury [published correction appears in Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1185]. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S123-S129. https://doi.org/10.1016/j.ijrobp.2009.03.07810.1016/j.ijrobp.2009.03.078
- 17. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arctherapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D conformal RT for treatment of prostate cancer. Radiother Oncol 2009; 93:226-233. https://doi.org/10.1016/j.radonc.2009.08.01110.1016/j.radonc.2009.08.011
- 18. Shaw E, Kline R, Gillin M, et al. Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys. 1993;27:1231-1239. https://doi.org/10.1016/0360-3016(93)90548-a10.1016/0360-3016(93)90548-A
- 19. Feuvret L, Noël G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys. 2006;64(2):333-42. https://doi.org/10.1016/j.ijrobp.2005.09.02810.1016/j.ijrobp.2005.09.028
- 20. Kataria T, Sharma K, Subramani V, et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys. 2012;37(4):207-213. https://doi.org/10.4103/0971-6203.10360610.4103/0971-6203.103606
- 21. Ning ZH, Mu JM, Jin JX, et al. Single arc volumetric-modulated arc therapy is sufficient for nasopharyngeal carcinoma: a dosimetric comparison with dual arc VMAT and dynamic MLC and step-and-shoot intensity-modulated radiotherapy. Radiat Oncol. 2013;8:237. https://doi.org/10.1186/1748-717X-8-23710.1186/1748-717X-8-237
- 22. Skórska M, Piotrowski T. Optimization of treatment planning parameters used in tomotherapy for prostate cancer patients. Phys Med. 2013;29(3):273-85. https://doi.org/10.1016/j.ejmp.2012.03.00710.1016/j.ejmp.2012.03.007
- 23. Cao D, Holmes TW, Afghan MK, Shepard DM. Comparison of plan quality provided by intensity-modulated arc therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;69(1):240-50. https://doi.org/10.1016/j.ijrobp.2007.04.07310.1016/j.ijrobp.2007.04.073
- 24. Tsai CL, Wu JK, Chao HL, et al. Treatment and dosimetric advantages between VMAT, IMRT, and helical tomotherapy in prostate cancer. Med Dosim. 2011;36(3):264-71. https://doi.org/10.1016/j.meddos.2010.05.00110.1016/j.meddos.2010.05.001
- 25. Rong Y, Tang G, Welsh JS, et al. Helical tomotherapy versus single-arc intensity-modulated arctherapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys. 2011;81(1):284-96. https://doi.org/10.1016/j.ijrobp.2010.10.05910.1016/j.ijrobp.2010.10.059
- 26. Ishii K, Ogino R, Okada W, et al. A dosimetric comparison of RapidArc and IMRT with hypofractionated simultaneous integrated boost to the prostate for treatment of prostate cancer. Br J Radiol. 2013;86(1030):20130199. https://doi.org/10.1259/bjr.2013019910.1259/bjr.20130199
- 27. Davidson MT, Blake SJ, Batchelar DL, et al. Assessingthe role of volumetricmodulatedarctherapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1550-8. https://doi.org/10.1016/j.ijrobp.2010.10.02410.1016/j.ijrobp.2010.10.024
- 28. Pasquier D, Cavillon F, Lacornerie T, et al. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(2):549-554. https://doi.org/10.1016/j.ijrobp.2012.03.04610.1016/j.ijrobp.2012.03.046
- 29. Servagi-Vernat S, Giraud P, Fenoglietto P, et al. Apport de la RCMI rotationnelle et de la tomothérapiehélicoïdaledans les cancers pelviens : étudedosimétrique prospective sur 51 patients [Impact of dynamic IMRT and tomotherapy in pelvic cancers: a prospective dosimetric study with 51 patients]. Cancer Radiother. 2014;18(2):111-118. https://doi.org/10.1016/j.canrad.2013.12.00810.1016/j.canrad.2013.12.008
- 30. Abu-Gheida I, Reddy CA, Kotecha R, et al. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):325-333. https://doi.org/10.1016/j.ijrobp.2019.01.09110.1016/j.ijrobp.2019.01.091
- 31. Widesott L, Pierelli A, Fiorino C, et al. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys. 2011;80(5):1589-1600. https://doi.org/10.1016/j.ijrobp.2010.10.00510.1016/j.ijrobp.2010.10.005
- 32. Barelkowski T, Wust P, Kaul D, et al. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. Strahlenther Onkol. 2020;196(3):229-242. https://doi.org/10.1007/s00066-019-01562-210.1007/s00066-019-01562-2
- 33. Beck M, Wust P, Barelkowski T, et al. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. Radiat Oncol. 2017;12(1):125. https://doi.org/10.1186/s13014-017-0862-410.1186/s13014-017-0862-4